原因不明の脳卒中および高リスクの卵円孔開存を有する高齢患者における心房細動の有病率および臨床的影響の評価 (DefenseElderly)
The purpose of DEFENSE-ELDERLY is to identify the prevalence of AF and evaluate the clinical impact of AF in elderly ESUS patients and no other known sources of stroke besides a high-risk patent foramen ovale, and compare it with elderly ESUS patients without high-risk PFO (no PFO or non-high risk PFOs)
調査の概要
詳細な説明
The purpose of DEFENSE-ELDERLY is to identify the prevalence of AF and evaluate the clinical impact of AF in elderly ESUS patients and no other known sources of stroke besides a high-risk patent foramen ovale, and compare it with elderly ESUS patients without high-risk PFO (no PFO or non-high risk PFOs)
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Seoul、韓国
- Asan Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature) (cohort A) and Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO (cohort B)
説明
Inclusion Criteria:
- Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature) (cohort A)
- Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO (cohort B)
- The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the institutional review board
- Patients who are scheduled to have implantable cardiac monitoring
Exclusion Criteria:
-
Transient ischemic attack
-
Lacunar infarction (infarction at subcortical area with a lesion diameter less than 2cm on MR)
-
Presence of complex aortic atheroma (≥4mm in plaque thickness or presence of mobile components)
-
Presence of ≥50% luminal stenosis (extra- or intracranial) in arteries supplying the ischemic area
-
Unwillingness or inability to comply with the procedures described in this protocol
-
Life expectancy < 1 years for any non-cardiac or cardiac causes
- High-risk anatomical feature of PFO; 1 of the 4 criteria described below PFO with an atrial septal aneurysm (protrusion of the dilated segment of the septum at least 15 mm beyond the level surface of the atrial septum), hypermobility (phasic septal excursion into either atrium ≥10mm), or PFO size (maximum separation of the septum primum from the secundum during the Valsalva maneuver >2 mm), appearance of more than 30 microbubbles in the left atrium within three cardiac cycles after opacification of the right atrium.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Cohort A
Cryptogenic Stroke with High-Risk PFO |
If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice. |
|
Cohort B
Cryptogenic Stroke without PFO or with Non-High-Risk PFO |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Paroxysmal Atrial Fibrillation Detected Within 6 Months
時間枠:Enrollment to 6 months
|
Paroxysmal AF episodes > 30 seconds detected with intermittent recordings or ≥ 2 minutes during ICM within 6 months |
Enrollment to 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Paroxysmal Atrial Fibrillation Detected at 6 and 36 Months
時間枠:At 6 and 36 months after enrollment
|
Paroxysmal AF episodes > 30 seconds detected with intermittent recordings or ≥ 2 minutes during ICM within 36 months |
At 6 and 36 months after enrollment
|
|
Number of Participants with Paroxysmal Atrial Fibrillation Detected at 6 and 36 Months
時間枠:At 6 and 36 months after enrollment
|
Paroxysmal AF episodes > 30 seconds detected with intermittent recordings or ≥ 6 minutes during ICM at 6 months and 36 months |
At 6 and 36 months after enrollment
|
|
Rate of Participants Undergoing Percutaneous PFO Device Closure
時間枠:From enrollment to 36 months
|
Proportion of participants who underwent percutaneous device closure of PFO. |
From enrollment to 36 months
|
|
Rate of Participants Prescribed Anticoagulants
時間枠:From enrollment to 36 months
|
Proportion of participants prescribed anticoagulants, including warfarin or direct oral anticoagulants (DOACs). |
From enrollment to 36 months
|
|
Number of Participants with Recurrent Stroke or Transient Ischemic Attack (TIA)
時間枠:From enrollment to 36 months
|
Number of participants who experienced recurrent stroke or transient ischemic attack (TIA) during follow-up. |
From enrollment to 36 months
|
|
Number of Participants with All-Cause Death
時間枠:From enrollment to 36 months
|
Number of participants who died from any cause during follow-up. |
From enrollment to 36 months
|
協力者と研究者
スポンサー
協力者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2019-1112
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。